KR102448526B1 - A preventing composition comprising CAPE, Quercetin and Chrysin for anti-inflammation - Google Patents

Abstract

The present invention relates to an anti-inflammatory composition comprising CAPE, quercetin and chrysin. CAPE (Caffeic acid phenethyl ester), quercetin, and chrysin mixture of the present invention can effectively inhibit NO production without toxicity, and particularly, the effect of inhibiting NO production induced by inflammation during pre-inflammatory treatment is very excellent, It can be widely used for the prevention of inflammation, and can be usefully used in various fields such as health functional foods, pharmaceuticals, cosmetics, and quasi-drugs for the purpose of preventing inflammation.

Description

A preventing composition comprising CAPE, Quercetin and Chrysin for anti-inflammation

The present invention relates to an anti-inflammatory composition comprising CAPE, quercetin and chrysin.

In modern society, the average lifespan of human beings has increased due to the development of medicine, and thus we are entering an aging society. Recently, along with the well-being craze, awareness of natural ingredients derived from plants is increasing. In the case of herbal medicines derived from all parts of medicinal plants, such as roots, fruits, flower bark, stems, leaves, and seeds of various plants, the safety and efficacy proven through prescriptions passed down from the past have been recognized. , bio foods, oriental medicine cosmetics, etc., are being used in various products using herbal medicines as raw materials. In addition, many studies are being conducted on functional materials such as pharmaceuticals and cosmetics using natural products that are friendly to the human body and have low side effects.

The inflammatory response, which is a kind of immune response, is a defense mechanism of the human body after a harmful stimulus is applied by microorganisms or compounds, and refers to all processes from the removal of the stimulus to the repair process of the damaged tissue. When an inflammatory reaction occurs chronically, it is reported that excessive secretion of inflammatory mediators is involved in various pathological mechanisms, such as promoting the growth of cancer cells or exacerbating arteriosclerosis by increasing insulin resistance. In the immune system, macrophages regulate inflammatory responses and immune function, and play an important role in maintaining homeostasis. The activity is increased by stimulation of LPS (Lipopolysaccharide), which is a complex of lipids and polysaccharides covalently bound to an external antigen, endotoxin, which is mainly present as a component of the outer membrane of Gram-negative bacteria. )to be. Macrophages activated by stimulation promote secretion of pro-inflammatory cytokines such as TNF-α (tumor necrosis factor-α), IL (interleukin)-1β, and IL-6. When these inflammatory mediators are formed, arachidonic acid is converted into leukotriene, thromboxane, prostaglandin, etc. through the action of cyclooxygenase (COX) and is involved in the mass production of NO (nitric oxide), thereby playing a major role in mediating inflammation and causing the host's lethality. known to cause damage. Among them, NO, a free radical, is a highly reactive substance and is produced from L-arginine by NOS (NO synthase), and NOS is divided into two groups: cNOS (constitutive NOS) and iNOS (inducible NOS). In particular, when iNOS is stimulated by external stimuli or pro-inflammatory cytokines, it is reported that it is expressed in various cells and produces a large amount of NO. Excessive production of NO is known to cause an inflammatory response and cause abnormalities in the immune system.

Therefore, research is underway to prevent and treat inflammatory responses by targeting NO production.

Accordingly, the present inventors have completed the present invention by confirming that a mixture of CAPE, quercetin and chrysin surprisingly can exhibit a specific and excellent effect in the prevention of inflammation while researching on a substance capable of effectively inhibiting NO production.

Accordingly, an object of the present invention relates to a health functional food, cosmetic, quasi-drug, and pharmaceutical composition for preventing inflammation comprising at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin.

In order to solve the above problems, the present invention provides a health functional food composition for preventing inflammation comprising at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin.

In addition, the present invention provides a cosmetic composition for preventing inflammation comprising at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin.

In addition, the present invention provides a quasi-drug composition for preventing inflammation, comprising at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin.

In addition, the present invention provides a pharmaceutical composition for preventing inflammatory diseases, comprising at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin.

CAPE (Caffeic acid phenethyl ester), quercetin, and chrysin mixture of the present invention can effectively inhibit NO production without toxicity, and particularly, the effect of inhibiting NO production induced by inflammation during pre-inflammatory treatment is very excellent, It can be widely used for the prevention of inflammation, and can be usefully used in various fields such as health functional foods, pharmaceuticals, cosmetics, and quasi-drugs for the purpose of preventing inflammation.

1 is a diagram showing the results of confirming the NO production inhibitory effect according to the CAPE (Caffeic acid phenethyl ester), quercetin or chrysine mixture of the present invention before LPS treatment, after LPS treatment, and simultaneously with LPS treatment (→ LPS: CAPE, quercetin or chrysine mixture pre-treatment group, LPS→: LPS stimulation induction followed by CAPE, quercetin or chrysine mixture treatment group, +LPS: CAPE, quercetin or chrysine mixture and LPS stimulation simultaneous treatment group).

The present invention provides a health functional food composition for preventing inflammation, a cosmetic composition, a quasi-drug composition, and a pharmaceutical composition comprising at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin.

CAPE, quercetin and chrysin of the present invention do not have in vivo toxicity, inhibit NO production, inhibit the expression of iNOS and COX-2, which are inflammatory factors, and pro-inflammatory cytokines IL-1βIL-6 and TNF Since it can have an excellent anti-inflammatory effect, such as suppressing the expression of -α, it can be usefully used in various fields such as pharmaceuticals, cosmetics, health functional foods, food, and various supplements.

Hereinafter, the present invention will be described in more detail.

CAPE of the present invention is a flavonoid-based component known as vitamin P, and may be represented by C ₁₇ H ₁₆ O ₄ and Formula 1 below. CAPE is a substance known as one of the components contained in propolis, honey, and beeswax.

[Formula 1]

In the present invention, quercetin is one of the flavonoids, and is a compound represented by the chemical formula of C ₁₅ H ₁₀ O ₇ and Chemical Formula 2 below. Quercetin is known to be a component contained in onions a lot, and is known to have effects such as cholesterol suppression and hypertension prevention.

[Formula 2]

In the present invention, chrysin is also called 5,7-dihydroxyflavone, and is one of the flavonoids identified in honey and propolis. Chrysine may be represented by C ₁₅ H ₁₀ O ₄ Chemical Formulas and Chemical Formula 3 below.

[Formula 3]

The present invention relates to a composition for preventing inflammation, comprising two or more mixtures or combination preparations selected from the group consisting of CAPE, quercetin and chrysin as an active ingredient, CAPE and quercetin, CAPE and chrysin, quercetin and chrysin, CAPE , a mixture of quercetin and chrysin or a combination preparation may be an active ingredient.

When CAPE and quercetin are included as active ingredients, CAPE and quercetin may be included in 1: 20 to 30 (w/v), preferably 1: 20 to 25 (w/v). In one embodiment of the present invention, the anti-inflammatory effect was confirmed by mixing CAPE 1μg/mL and quercetin 25μg/mL.

When CAPE and chrysin are included as active ingredients, CAPE and chrysin may be included in 1: 20 to 30 (w/v), preferably 1: 20 to 25 (w/v). In one embodiment of the present invention, the anti-inflammatory effect was confirmed by mixing CAPE 1μg/mL and chrysin 25μg/mL.

When quercetin and chrysin are included as active ingredients, quercetin and chrysin may be included in 1:1 to 3 (w/v), preferably 1:1 to 2 (w/v). In one embodiment of the present invention, quercetin 25 μg/mL and chrysin 25 μg/mL were mixed to confirm the anti-inflammatory effect.

In addition, the anti-inflammatory composition of the present invention may include all of CAPE (caffeic acid phenethyl ester), quercetin and chrysin as an active ingredient, preferably, CAPE, quercetin and chrysin 1: 20 to 30: 20 to 30 (w/ v) can be included. In one embodiment of the present invention, the anti-inflammatory effect was confirmed by mixing quercetin 25 μg/mL, chrysin 25 μg/mL and CAPE 1 μg/mL.

In the present invention, when two or more selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin are mixed, a better anti-inflammatory effect compared to the anti-inflammatory effect that can be exhibited by individual components thereof. In particular, the composition of the present invention may be characterized as an excellent composition for preventing inflammation by pre-treatment at the same time or before the occurrence of inflammation. In particular, when the composition of the present invention is pre-treated for the purpose of preventing inflammation, it may exhibit an inflammatory response inhibitory effect of about 7 to 10 times or more compared to the treatment after inflammation.

Accordingly, at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin, and chrysin of the present invention can be administered before inflammation occurs, at least simultaneously with inflammation, to prevent inflammation.

CAPE, quercetin and chrysin of the present invention may be provided in a mixed form, and may be administered in combination in a sequential manner.

In the present invention, “health functional food” refers to a food group or food composition that has added value to act and express the function of the food for a specific purpose using physical, biochemical, and bioengineering methods, etc. It refers to food that has been designed and processed to sufficiently express the body control functions related to disease prevention and recovery. For the purpose of the present invention, the health functional food is to promote anti-inflammatory activity, for example, refers to a health functional food for preventing and improving inflammatory diseases caused by the production of nitric oxide.

In the present invention, the food composition can be prepared by a method commonly used in the art, and during the preparation, it can be prepared by adding raw materials and components commonly added in the art. In addition, if the formulation of the food composition is also recognized as a food composition, it may be prepared without limitation.

Foods according to the present invention include, for example, various foods, beverages, gum, tea, vitamin complexes, functional foods, and the like. In addition, food includes special nutritional food (eg, formula milk, infant food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (eg, ramen, noodles, etc.), breads, health supplements, seasoned foods (eg, soy sauce). , soybean paste, red pepper paste, mixed paste, etc.), sauces, confectionery (eg snacks), candy, chocolate, gum, ice cream, dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various kimchi) , pickles, etc.), beverages (eg, fruit beverages, vegetable beverages, soy milk, fermented beverages, etc.), natural seasonings (eg, ramen soup, etc.), food additives, etc., but are not limited thereto. The food, beverage or food additive may be prepared by a conventional manufacturing method.

When the composition of the present invention is used as a health functional food additive, the composition may be added as it is or may be used together with other health functional food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be suitably determined according to the purpose of use. In general, in the production of food or beverage, the composition of the present invention may be added in an amount of preferably 50 parts by weight or less, more preferably 25 parts by weight or less, based on the raw material. However, in the case of long-term intake for the purpose of health control and hygiene, the amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount above the above range.

The food or health functional food composition of the present invention contains various flavoring agents or natural carbohydrates, etc. as additional ingredients, as in a conventional food composition, in addition to containing a mixture of the active ingredients CAPE (Caffeic acid phenethyl ester), quercetin and chrysin can do. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin, cyclodextrin, and the like, and sugar alcohols such as xylitol, sorbitol, erythritol and the like. The above-mentioned flavoring agent can advantageously use natural flavoring agent (Taumatine), stevia extract (eg rebaudioside A, glycyrrhizine, etc.) and synthetic flavoring agent (saccharin, aspartame, etc.).

In addition, the food composition is a mixture of CAPE (Caffeic acid phenethyl ester), quercetin and chrysin, and various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages.

The present invention also provides a cosmetic composition for preventing inflammation and a quasi-drug composition for preventing inflammation comprising at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin.

CAPE, quercetin, and two or more mixtures or combination preparations selected from chrysin of the present invention can exhibit an excellent effect in suppressing inflammatory reactions that may occur in the skin when repeatedly applied to the skin before inflammation occurs, and inflammatory action when inflammation occurs can be effectively suppressed.

In the present invention, the quasi-drug composition or cosmetic composition may be formulated as an ointment, a cream, a gel, a lotion, a liquid, a dressing, a patch, a blister, a tape, a mist, an external acid, and a spray. .

In the composition of the present invention, any component generally used in a quasi-drug composition or a cosmetic composition may be used.

For example, in the case of ointments, creams, gels and lotions, white petrolatum (Vaseline), yellow petrolatum, lanolin, refined beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, bases such as liquid paraffin and squalane; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamiton, diethyl sebacate, diisopropyl sebacate, diisopropyl adipate, hexylaulate, fatty acids, fatty acid esters, vegetable oils, fatty alcohols and solvents or stabilizers such as alcohols; antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; curbs such as glycerin, propylene glycol and sodium hyaluronate; surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin; thickeners such as carboxyvinylpolymer, xanthan gum, carboxymethyl cellulose and sodium carboxymethyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; stabilizers; preservatives; adsorption promoters; and other suitable fillers may be added.

In the case of the blistering agent, a pressure-sensitive adhesive such as polyacrylic acid and polyacrylic acid copolymer; crosslinking agents such as aluminum sulfate, aluminum potassium sulfate, aluminum chloride, magnesium aluminometasilicate and dihydroxyaluminum aminoacetate; thickeners such as sodium polyacrylate, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, sodium alginate, carboxymethylcellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; polyhydric alcohols such as glycerin, polyethylene glycol (macrogol), polyethylene glycol and 1,3-butanediol; surfactants such as polyoxyethylene derivatives; flavorings such as l-menthol; preservatives such as p-hydroxybenzoate; Purified water; and other suitable fillers may be added.

In the case of the tape agent, an adhesive such as a styrene-isoprene-styrene block copolymer and an acrylate resin; adhesive resins such as acrylic saturated hydrocarbon resins, hydrogenated rosine resins and terpene resins; softeners such as liquid gums and liquid paraffin; antioxidants such as dibutylhydroxytoluene; polyhydric alcohols such as polyethylene glycol; adsorption promoters such as oleic acid; surfactants such as polyoxyethylene derivatives; and other suitable fillers may be added. In addition, a water-absorbing polymer such as sodium polyacrylate and polyvinyl alcohol and a small amount of purified water may be added to the preparation of the water-containing tape agent.

For aerosols, bases such as white petrolatum (Vaseline), yellow petrolatum, lanolin, refined beeswax, cetanol, stearyl alcohol, stearic acid, hydrogenated oil, hydrocarbon gel, polyethylene glycol, liquid paraffin and squalane; Oleic acid, isopropyl myristate, glycerol triisooctanoate, crotamiton, diethyl sebacate, diisopropyl sebacate, isopropyl adipate, hexyl laurate, fatty acids, fatty acid esters, vegetable oils, fatty alcohols and alcohols solvents or stabilizers such as; antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene and butylhydroxyanisole; preservatives such as p-hydroxybenzoate; curbs such as glycerin, propylene glycol and sodium hyaluronate; Surfactants such as polyoxyethylene derivatives, glycerol fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and lecithin Carboxyvinyl polymers such as those used in ointments, creams, gels or lotions, xanthan gum, carboxymethyl thickeners such as cellulose and sodium carboxymethyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; stabilizers; buffer; sweetener suspending agent; emulsifiers; Condiment; antiseptic; Adsorption promoters and other suitable fillers may be added.

In the case of the external powder, fillers such as potato starch, rice starch, corn starch, talc and zinc oxide, and other suitable additives may be added.

The quasi-drug composition or cosmetic composition of the present invention can be prepared by blending various known ingredients to be formulated in a composition applied to the skin or mucous membrane, and according to a well-known method for preparing an external preparation for skin or cosmetic composition, a suitable base as needed Together, it can be prepared by mixing each component well, and the preparation thus prepared is applied to the lesion as needed.

CAPE, quercetin, and two or more mixtures or combination preparations selected from chrysin according to the present invention are 0.0001 to 50% by weight, preferably 1 to 30% by weight based on the total weight of the quasi-drug composition or cosmetic composition of the present invention. When the content is less than 0.0001% by weight, the anti-inflammatory effect cannot be achieved, and when it exceeds 50% by weight, formulation is difficult and the feeling of use may be reduced.

In addition, the present invention provides a pharmaceutical composition for preventing inflammatory diseases, comprising at least two selected from the group consisting of caffeic acid phenethyl ester (CAPE), quercetin and chrysin.

In the present invention, the pharmaceutical composition for preventing inflammatory diseases may be to prevent inflammatory diseases by specifically inhibiting the production of nitric oxide and suppressing the expression of inflammatory factors and pro-inflammatory cytokines.

The inflammatory disease refers to diseases whose main lesion is inflammation, and is not limited thereto, but allergic diseases including, but not limited to, allergic asthma, allergic rhinitis, allergic mucositis, urticaria and anaphylax; Myopathy including systemic sclerosis, dermatomyositis and inclusion body myositis, arthritis, atopic dermatitis, psoriasis, asthma, multiple sclerosis, sepsis, polychondritis, scleroderma, eczema, gout, periodontitis disease, Behcet's syndrome, edema, vasculitis, Kawasaki disease, diabetic retinitis, autoimmune pancreatitis, vasculitis, glomerulonephritis, acute and chronic bronchitis, influenza infection, and the like.

In the present invention, the pharmaceutical composition may be formulated and used in various forms according to a conventional method. For example, it may be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and may be formulated in the form of external preparations, suppositories, and sterile injection solutions.

The pharmaceutical composition of the present invention may be prepared by including one or more pharmaceutically acceptable carriers in addition to the active ingredients for administration. Pharmaceutically acceptable carriers included in the pharmaceutical composition of the present invention are commonly used in formulation, and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. it's not going to be The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like, in addition to the above components.

The dosage of the pharmaceutical composition of the present invention may vary depending on the formulation method, administration method, administration time and/or route of administration of the pharmaceutical composition, and the type and degree of response to be achieved by administration of the pharmaceutical composition. , various factors including the type of subject to be administered, age, weight, general health, symptoms or severity of disease, sex, diet, excretion, components of drugs or other compositions used simultaneously or at the same time in the subject; It may vary depending on similar factors well known in the medical field, and a person skilled in the art can easily determine and prescribe an effective dosage for a desired treatment.

The dosage of the pharmaceutical composition of the present invention may be, for example, 1 mg/kg to 1,000 mg/kg per day, but the dosage is not intended to limit the scope of the present invention in any way.

The route and mode of administration of the pharmaceutical composition of the present invention may be each independent, and the method is not particularly limited, and any route and mode of administration as long as the pharmaceutical composition can reach the desired site. can follow

The pharmaceutical composition may be administered by oral administration or parenteral administration. The parenteral administration method includes, for example, intravenous administration, intraperitoneal administration, intramuscular administration, transdermal administration, or subcutaneous administration, and methods of applying, spraying, or inhaling the pharmaceutical composition to the diseased site may also be used. However, the present invention is not limited thereto.

The content overlapping with the above-described content is omitted to avoid the complexity of the description, and the overlapping content may be equally applied.

Hereinafter, the present invention will be described in detail by way of Examples. The following examples are only for illustrating the present invention, but the present invention is not limited by the following examples.

Example 1. CAPE, quercetin , chrysin Check anti-inflammatory effect

CAPE (Caffeic acid phenethyl ester), quercetin, and chrysin were treated with RAW264.7 cells, a mouse-derived macrophage cell line (Korean Cell Line Bank, Seoul, Korea), and the anti-inflammatory effect of these mixtures was confirmed. Cells were cultured using DMEM (Dulbecco's modified eagle's medium; Gibco, Grand Island, NY, USA) supplemented with 10% FBS (fetal bovine serum; GenDEPOT, TX, USA), 100 units/mL penicillin, and 100 µg/mL streptomycin. 37° C., 5% CO ₂ Incubated in an incubator.

In order to confirm the anti-inflammatory effect, the degree of inhibition of NO (nitric oxide) production was confirmed. NO is involved in physiological processes such as blood coagulation, regulation of blood pressure and neurotransmission function, and plays an important role in maintaining cell function depending on the concentration, but high concentration of NO production causes inflammation, tissue damage, genetic mutation, etc. causes In addition, it is known that high-concentration NO production plays an important role in the formation and progression of cancer by generating harmful substances, causes accumulation of harmful oxidizing substances in cells, damages DNA, and causes apoptosis.

First, Raw 264.7 cells were seeded in a 96-well plate at a final concentration of 2×10 ⁵ cells/well. The cells were cultured at 37° C., 5% CO ₂ in an incubator for 24 hours. In order to confirm the anti-inflammatory effect of CAPE, quercetin, and chrysin mixed treatment and the effect according to the treatment sequence, CAPE 1μg/mL, quercetin 25μg/mL and chrysin 25μg/mL were treated before, simultaneously with, and after LPS 1μg/ml treatment and the change in the amount of NO production was confirmed. The experimental groups are summarized in Table 1 below.

treatment method experimental group LPS Pretreatment Quercetin 25 μg/mL and Chrysin 25 μg/mL Quercetin 25 μg/mL and CAPE 1 μg/mL Chrysin 25 μg/mL and CAPE 1 μg/mL Quercetin 25 μg/mL, Chrysin 25 μg/mL and CAPE 1 μg/mL LPS Concurrent processing Quercetin 25 μg/mL and Chrysin 25 μg/mL Quercetin 25 μg/mL and CAPE 1 μg/mL Chrysin 25 μg/mL and CAPE 1 μg/mL Quercetin 25 μg/mL, Chrysin 25 μg/mL and CAPE 1 μg/mL LPS After treatment Quercetin 25 μg/mL and Chrysin 25 μg/mL Quercetin 25 μg/mL and CAPE 1 μg/mL Chrysin 25 μg/mL and CAPE 1 μg/mL Quercetin 25 μg/mL, Chrysin 25 μg/mL and CAPE 1 μg/mL

NO inhibitory activity was measured using a NO plus detection kit (iNtRON, MA, USA), and it was carried out according to the experimental method recommended by the manufacturer. Absorbance was measured at 540 nm using a microplate reader, NO production was calculated by creating a standard curve (Nitrite), and the NO suppression result is shown in FIG. 1 .

As shown in Figure 1, in the experimental group treated with CAPE, quercetin or chrysin and stimulated with LPS, and the experimental group treated with CAPE, quercetin or chrysin and LPS at the same time, NO production was significantly inhibited compared to the inflammatory stimulation test group treated with LPS alone. It was confirmed that it can exhibit an anti-inflammatory effect. On the other hand, in the experimental group pre-treated with LPS and post-treated with CAPE, quercetin or chrysin, the effect of inhibiting NO production by LPS was weak. In particular, in the experimental group treated with CAPE, quercetin or chrysin before or simultaneously with the inflammatory stimulation, compared to the experimental group treated with CAPE, quercetin or chrysin after LPS inflammatory stimulation, the NO production inhibitory effect was about 7 to 10 times. Based on these results, it was confirmed that the mixed treatment of CAPE, quercetin, or chrysin had a very excellent protective and preventive effect on the inflammatory stimulus during the pre-inflammatory treatment rather than the inhibition of the already generated inflammation.

Hereinafter, formulation examples of the composition of the present invention will be described, but the present invention is not intended to limit the present invention, but merely to describe in detail.

Formulation example 1. Preparation of pharmaceutical compositions

1- 1. powdery Produce

2 g of a mixture of CAPE, quercetin or chrysin

1 g lactose

The above ingredients were mixed and filled in an airtight cloth to prepare a powder.

1- 2. Preparation of tablets

100 mg of a mixture of CAPE, quercetin or chrysin

100 mg cornstarch

Lactose 100 mg

2 mg magnesium stearate

After mixing the above ingredients, tablets were prepared by tableting according to a conventional manufacturing method of tablets.

1-3. manufacture of capsules

100 mg of a mixture of CAPE, quercetin or chrysin

100 mg cornstarch

Lactose 100 mg

2 mg magnesium stearate

After mixing the above ingredients, the capsules were prepared by filling in gelatin capsules according to a conventional manufacturing method of capsules.

Formulation example 2. External preparations for skin/ cosmetics Preparation of the composition

2-1. Manufacture of softening lotion (skin lotion)

Mixture of CAPE, quercetin or chrysin 0.5%

Beta-1,3-glucan 1.0%

Butylene Glycol 2.0 %

Propylene glycol 2.0 %

Carboxyvinyl Polymer 0.1 %

PEG-12 Nonylphenyl Ether 0.2 %

Polysorbate 80 0.4%

Ethanol 10.0%

Triethanolamine 0.1%

Preservatives, colors and fragrances

Purified water to 100 %

2-2. preparation of cream

A mixture of CAPE, quercetin or chrysin 1.0%

Beta-1,3-glucan 5.0%

beeswax 10.0%

Polysorbate 60 1.5%

Sebum 60 hydrogenated castor oil 2.0%

Sorbitan sesquioleate 0.5%

Liquid paraffin 10.0 %

Squalane 5.0%

Caprylic/Capric Triglycerides 5.0 %

Glycerin 5.0%

Butylene Glycol 3.0 %

Propylene glycol 3.0 %

Triethanolamine 0.2%

Appropriate amount of preservatives, colors, and fragrances

Purified water to 100 %

Claims (11)

CAPE (Caffeic acid phenethyl ester), quercetin and chrysin 1: 20 to 30: 20 to 30 (w / v) comprising, a health functional food composition for preventing inflammation.
delete delete delete delete delete delete According to claim 1, CAPE (Caffeic acid phenethyl ester), quercetin and chrysin 1: 25: 25 (w / v) comprising, the health functional food composition for preventing inflammation.
CAPE (Caffeic acid phenethyl ester), quercetin and chrysin 1: 20 to 30: 20 to 30 (w / v) comprising a, a cosmetic composition for preventing inflammation.
CAPE (Caffeic acid phenethyl ester), quercetin and chrysin 1: 20 to 30: 20 to 30 (w / v) comprising, a quasi-drug composition for preventing inflammation. delete

Images